Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Jazz Pharma Plc (JAZZ)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Jazz Pharma Plc FIFTH FLOOR WATERLOO EXCHANGE WATERLOO ROAD DUBLIN L2 D04 IRL

www.jazzpharmaceuticals.com P: 353-1634-7800 F: 353-163-4785

Description:

Jazz Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on identifying, developing and commercializing innovative products to meet unmet medical needs in neurology and psychiatry. Company's goal is to build a broad portfolio of products through a combination of internal development and acquisition/in-licensing activities and to utilize our specialty sales force to promote products in our target markets. They apply novel formulations and drug delivery technologies to known drug compounds, and compounds with the same mechanism of action or similar chemical structure as marketed products, to improve patient care by improving efficacy, reducing adverse side effects or increasing patient compliance relative to existing therapies. Based in Palo Alto, California, the company is committed to working closely with patients, patient advocacy groups and healthcare professionals.

Key Statistics

Overview:

Market Capitalization, $K 9,682,302
Shares Outstanding, K 60,090
Annual Sales, $ 1,488 M
Annual Net Income, $ 396,830 K
36-Month Beta 1.11
% of Insider Shareholders 4.30%
% of Institutional Shareholders 85.91%

Growth:

1-Year Total Return 13.50%
3-Year Total Return 8.91%
5-Year Total Return 245.18%
5-Year Revenue Growth 446.49%
5-Year Earnings Growth 104.79%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings 2.31 on 05/09/17
Next Earnings Date 08/08/17
Earnings Per Share ttm 7.28
EPS Growth vs. Prev Qtr -26.18%
EPS Growth vs. Prev Year -24.60%
Annual Dividend Rate, $ 0.00
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00

JAZZ Ratios

Ratio
Price/Earnings ttm 21.96
Price/Earnings forward 22.10
Price/Earnings to Growth 1.25
Return on Equity % 21.14
Return on Assets % 9.96
Profit Margin % 26.67
Debt/Equity 1.06
Price/Sales 6.46
Price/Cash Flow 17.97
Price/Book 4.84
Book Value/Share 33.06
Interest Coverage 7.15
Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.